Trial Profile
An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; KHK 2455 (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development
- 13 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Feb 2022 Planned End Date changed from 25 Feb 2022 to 28 Feb 2024.
- 18 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 30 Sep 2023.